V M L Cohen1, J Kingston, J L Hungerford. 1. St Bartholomew's and the Royal London Hospital, West Smithfield, London EC1A 7BE, UK. victoria.lendrum@gmail.com
Abstract
AIMS: To report the ocular survival and event-free survival following primary multiagent chemotherapy for group D, heritable bilateral retinoblastoma (RB). METHODS: The RB database was used to identify children with heritable, bilateral RB treated with primary chemotherapy (six cycles of vincristine, etoposide and carboplatin). Only Group D eyes with more than 12 months' follow-up were analysed. The timing, number and type of salvage treatments were recorded. Kaplan-Meier estimates for the ocular survival and event-free survival (percentage of eyes that avoided external beam radiotherapy and/or enucleation) were performed as a function of time. RESULTS: Of 18 group D eyes, two (11%) were treated successfully with chemotherapy alone, nine (50%) underwent successful salvage treatment, and seven (39%) were enucleated. The median time from completing chemotherapy to enucleation was 9 months (range 4 to 25 months). Ocular survival was 67% at 2 years. External beam radiotherapy proved successful salvage treatment in five of nine eyes, so the event-free survival was 34% at 2 years. CONCLUSION: Multiagent chemotherapy alone is rarely sufficient for the preservation of group D eyes. External beam radiotherapy and plaque radiotherapy remain important salvage treatments for advanced, heritable retinoblastoma.
AIMS: To report the ocular survival and event-free survival following primary multiagent chemotherapy for group D, heritable bilateral retinoblastoma (RB). METHODS: The RB database was used to identify children with heritable, bilateral RB treated with primary chemotherapy (six cycles of vincristine, etoposide and carboplatin). Only Group D eyes with more than 12 months' follow-up were analysed. The timing, number and type of salvage treatments were recorded. Kaplan-Meier estimates for the ocular survival and event-free survival (percentage of eyes that avoided external beam radiotherapy and/or enucleation) were performed as a function of time. RESULTS: Of 18 group D eyes, two (11%) were treated successfully with chemotherapy alone, nine (50%) underwent successful salvage treatment, and seven (39%) were enucleated. The median time from completing chemotherapy to enucleation was 9 months (range 4 to 25 months). Ocular survival was 67% at 2 years. External beam radiotherapy proved successful salvage treatment in five of nine eyes, so the event-free survival was 34% at 2 years. CONCLUSION: Multiagent chemotherapy alone is rarely sufficient for the preservation of group D eyes. External beam radiotherapy and plaque radiotherapy remain important salvage treatments for advanced, heritable retinoblastoma.
Authors: Christina Scelfo; Jasmine H Francis; Vikas Khetan; Thomas Jenkins; Brian Marr; David H Abramson; Carol L Shields; Jacob Pe'er; Francis Munier; Jesse Berry; J William Harbour; Andrey Yarovoy; Evandro Lucena; Timothy G Murray; Pooja Bhagia; Evelyn Paysse; Samuray Tuncer; Guillermo L Chantada; Annette C Moll; Tatiana Ushakova; David A Plager; Islamov Ziyovuddin; Carlos A Leal; Miguel A Materin; Xun-Da Ji; Jose W Cursino; Rodrigo Polania; Hayyam Kiratli; Charlotta All-Ericsson; Rejin Kebudi; Santosh G Honavar; Vicktoria Vishnevskia-Dai; Sidnel Epelman; Anthony B Daniels; Jeanie D Ling; Fousseyni Traore; Marco A Ramirez-Ortiz Journal: Int J Ophthalmol Date: 2017-06-18 Impact factor: 1.779
Authors: L Lumbroso-Le Rouic; I Aerts; D Hajage; C Lévy-Gabriel; A Savignoni; N Algret; N Cassoux; A-I Bertozzi; M Esteve; F Doz; L Desjardins Journal: Eye (Lond) Date: 2015-10-02 Impact factor: 3.775
Authors: Yevgeniy Shildkrot; Maria Kirzhner; Barrett G Haik; Ibrahim Qaddoumi; Carlos Rodriguez-Galindo; Matthew W Wilson Journal: Ophthalmology Date: 2011-12 Impact factor: 12.079
Authors: Joo Young Shin; Jeong Hun Kim; Young Suk Yu; Sang In Khwarg; Ho Kyung Choung; Hee Young Shin; Hyo Seop Ahn Journal: Korean J Ophthalmol Date: 2010-08-03
Authors: Ankit Agarwal; Nikhil G Thaker; Bouchra Tawk; Pamela K Allen; David R Grosshans; Cynthia E Herzog; Daniel S Gombos; Anita Mahajan Journal: Int J Part Ther Date: 2016-03-24
Authors: Anthony B Daniels; Shriji N Patel; Ronald W Milam; Sahar Kohanim; Debra L Friedman; Tatsuki Koyama Journal: Cancers (Basel) Date: 2021-05-06 Impact factor: 6.639
Authors: John T Lucas; Rose McGee; Catherine A Billups; Ibrahim Qaddoumi; Thomas E Merchant; Rachel C Brennan; Jiangrong Wu; Matthew W Wilson Journal: Br J Ophthalmol Date: 2018-06-28 Impact factor: 4.638